Orion Oyj has secured an exclusive licensing agreement with Criceto IKM B.V. for the commercialization of the innovative apomorphine oral spray (APORON®), aimed at treating OFF periods in Parkinson's disease patients.
Target Information
Orion Oyj has entered into an exclusive licensing agreement with Criceto IKM B.V. for the innovative apomorphine oral spray (APORON®), aimed at treating OFF periods in patients suffering from Parkinson's disease. As part of this agreement, Criceto is currently conducting a Phase 3 clinical trial for the APORON® spray, which is designed to provide a rapid-acting treatment solution for challenging OFF periods that significantly affect patients' quality of life.
Under the terms of the agreement, Orion has obtained the exclusive license for the development and commercialization of the apomorphine oral spray globally, excluding the United States and Canada. The arrangement also includes advance payments, compensation for development costs, and royalties on future commercial sales of the product.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The Parkinson's disease treatment market in Finland is witnessing a notable growth due to increasing awareness about the disease, coupled with advances in treatment opt
Similar Deals
Boston Scientific → Nalu Medical
2026
Barça Innovation Hub → Omniscope
2025
Orion Oyj
invested in
Criceto IKM B.V.
in 2025
in a Strategic Partnership deal
Disclosed details
Revenue: $1,542M